Urologix v. ProstaLund
This article was originally published in The Gray Sheet
Executive Summary
Motion for preliminary injunction against sales of ProstaLund's CoreTherm microwave thermotherapy system for benign prostatic hyperplasia is denied by Milwaukee federal court Judge Lynn Adelman, clearing the way for U.S. marketing, pending PMA approval "in the near future," ProstaLund says. Adelman also rules that one of two Urologix patents asserted against ProstaLund is invalid. ACMI will distribute the device...
You may also be interested in...
ProstaLund CoreTherm BPH Device Arrives In U.S., Distributed Through ACMI
ProstaLund will immediately fill $2.3 mil. in back-orders for its CoreTherm microwave transurethral benign prostatic hyperplasia (BPH) treatment device, approved via PMA in December
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.